Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Most basic cancer drugs remain inaccessible in low- and lower-middle-income countries
  • News

Most basic cancer drugs remain inaccessible in low- and lower-middle-income countries

  • 25 October 2021
  • Swagata Yadavar
Most basic cancer drugs remain inaccessible in low- and lower-middle-income countries
Total
0
Shares
0
0
0
0
0

Despite being available for more than 20 years, basic cancer drugs found to be most effective against the disease can still not be accessed by patients in most low- and lower-middle-income countries according to a new study. 

The paper, published in the Lancet Oncology, presents the findings of a questionnaire sent to oncologists from a range of clinical practice settings, from low- to high-income countries, which asked them to list the most important cancer medicines and to describe whether patients could access these medicines in their country. The researchers also wanted to find out whether the drugs listed in the Essential Medicines List (EML) published by the World Health Organization included the priority drugs listed by frontline oncologists globally.

The study, conducted among 948 oncologists in 82 countries, found that most important medicines identified by oncologists were the older, inexpensive chemotherapy and hormone medicines. Of the 20 highest-priority drugs identified by the oncologists, 19 are already included in the WHO’s EML. Most of the drugs identified by the oncologists have been available for more than 20 years and deliver large benefits over many cancers. 

Despite being older and included in the EML, access to these priority drugs varied considerably across the regions. In low- and lower-middle income countries, between 13% and 68% of respondents said that accessing the top 20 medicines placed patients at the risk of ‘catastrophic expenditure’. Catastrophic expenditure refers to medical treatment that costs more than 40% of the total consumption of the family after expenditure on food. 

This was the case in these countries even for the generic drugs doxorubicin and cisplatin, which were identified as inaccessible by one in four respondents. The only exception was the corticosteroid dexamethasone, which was identified as universally available by 50% of respondents. 

Access to the 20 highest-priority drugs was better in upper-middle-income countries, with more than half of respondents indicating universal availability of all bar three of the medicines. The risk of catastrophic expenditure was less than 10% for all 20 drugs; however, drugs approved in the 1990s and 2000s, such as like imatinib, trastuzumab and gemcitabine, incur considerable out-of-pocket expenditure.

In high-income countries, most of the 20 drugs were universally available, and the risk for catastrophic expenditure was less than 10% percent for all drugs; however, out of pocket expenditure was reported for drugs like osimertinib, imatinib and even older drugs like doxorubicin and paclitaxel.

The researchers noted that oncologists on the frontline prioritised older chemotherapy and hormonal drugs over new cancer drugs that are associated with marginal benefits. They commented that, despite being included in WHO’s EML, many of the drugs seen as highest priority may not have been sufficiently prioritised by country-level access policies, resulting in limited access to even the most basic drugs for cancer care. 

Speaking to Cancer World, co-author of the paper Christopher Booth, who is Professor of Oncology and Public Health Sciences and the Canada Research Chair in Population Cancer Care, Queen’s University, Ontario, called the findings ‘worrisome and sobering’, and advised that, “the WHO EML committee will need to carefully consider the implications about adding more new and expensive medicine to the EML when currently, the majority of oncologists worldwide can’t even access basic cancer medicines for patients that have huge benefits.”

He also suggested that the global oncology community will need to learn from the HIV community, which faced similar problems decades ago and, through advocacy and various policy tools, were able to make HIV drugs more affordable for patients globally. 

Manju Sengar, Professor of Medical Oncology at the Tata Memorial Hospital, Mumbai, who also co-authored the paper, emphasised that improving access to the cancer drugs with meaningful clinical benefit involved getting the cost down. “This can be done using the strategy for HIV drugs and medicine patent pool as well as negotiating the prices as a group for all the low- and lower-middle-income countries,” she said, adding that, “these drugs should get incorporated in their [countries’] essential medicine list, which can then be supported by their national health budgets to ensure universal access.”

The 20 top-priority cancer drugs according to frontline oncologists across the world

  1. Doxorubicin

  2. Cisplatin

  3. Pacilitaxel

  4. Pembrolizumab

  5. Trastuzumab

  6. Carboplatin

  7. 5-fluorouracil

  8. Tamoxifen

  9. Capecitabine

  10. Cyclophosphamide

  11. Docetaxel

  12. Oxaliplatin

  13. Dexamethasone
  14. 
Nivolumab

  15. Rituximab

  16. Imatinib

  17. Gemcitabine
  18. 
Etoposide

  19. Osimertinib (not in the current WHO EML)

  20. Letrozole (Substitute for drug in the WHO EML)
Top 20 medicines identified by almost 1000 oncologists across 82 low-income, lower- and upper-middle-income and high-income countries, in response to a request to select the ten cancer medicines that would provide the greatest public health benefit to their country
WHO EML – World Health Organization’s Essential Medicines List
Source: A Fundytus et al (2021) Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol 22:1367‒77
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • access
  • cancer drugs
  • WHO Essential Medicines List
Swagata Yadavar

Swagata Yadavar is an award-winning independent journalist based in New Delhi. She writes on public policy, healthcare and gender related themes. Previously, she worked with IndiaSpend, India's first data journalism website and The Week, a national magazine.

Previous Article
  • News

What’s new in lung and colorectal cancer? reports from ESMO 2021

  • 15 October 2021
  • Janet Fricker
View Post
Next Article
  • News

Atlas provides ‘one-stop shop’ for myeloma care information across Europe

  • 28 October 2021
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.